Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity

Journal of Medicinal Chemistry

Volumn 48, Issue 21, 2005, Pages 6553-6562

  Wittelsberger, Angela ^a,d   Patiny, Luc ^a   Slaninova, Jirina ^b   Barberis, Claude ^c   Mutter, Manfred ^a  

^a EPFL   (Switzerland)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c INSERM   (France)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; DIMETHYL SULFOXIDE; OXYTOCIN DERIVATIVE; OXYTOCIN RECEPTOR; OXYTOCIN[7 (CYSTINE PSI DIHYDROPROLINE)]; OXYTOCIN[7 (CYSTINE PSI DIMETHYLPROLINE)]; PROLINE DERIVATIVE; PSEUDOPROLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HORMONE ACTION; HUMAN; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN CONFORMATION; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BINDING, COMPETITIVE; BLOOD PRESSURE; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; OXYTOCIN; PROLINE; RADIOLIGAND ASSAY; RATS; RECEPTORS, OXYTOCIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; UTERINE CONTRACTION; UTERUS;

EID: 27144548997     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049205z     Document Type: Article

References (51)

1. Hruby, V. J.; Brewster, A. I.; Glasel, J. A. NMR studies on the conformation of derivatives of the side chain of oxytocin: Examples of cis-trans isomerism. PNAS 1971, 68, 450-453.
2. Brewster, A. I.; Hruby, V. J.; Spatola, A. F.; Bovey, F. A. Carbon-13 nuclear magnetic resonance spectroscopy of oxytocin, related oligopeptides, and selected analogues. Biochemistry 1973, 12, 1643-1649.
3. Deslauriers, R.; Walter, R.; Smith, I. C. A carbon-13 nuclear magnetic resonance study of oxytocin and its oligopeptides. Biochem. Biophys. Res. Commun. 1972, 48, 854-859.
4. Smith, I. C.; Deslauriers, R.; Walter, R. Chemistry and Biology of Peptides; Ann Arbor Science Publishers: Ann Arbor, MI, 1972; pp 29-34.
5. Larive, C. K.; Guerra, L.; Rabenstein, D. L. Cis/trans conformational equilibrium across the cysteine6-proline peptide bond of oxytocin, arginine vasopressin, and lysine vasopressin. J. Am. Chem. Soc. 1992, 114, 7331-7337.
6. Larive, C. K.; Rabenstein, D. L. Dynamics of cis/trans isomerization of the cysteine6-proline peptide bonds of oxytocin and arginine-vasopressin in aqueous and methanol solutions. J. Am. Chem. Soc. 1993, 115, 2833-2836.
7. Harrison, R. K.; Stein, R. L. Mechanistic studies of enzymic and nonenzymic prolyl cis-trans isomerization. J. Am. Chem. Soc. 1992, 114, 3464-3471.
8. Grzonka, Z.; Mishra, P. K.; Bothner-By, A. A. Conformational preferences and binding to neurophysins of oxytocin analogues with sarcosine or N-methylalanine in position 7. Int. J. Pept. Protein Res. 1985, 25, 375-381.
9. Grzonka, Z.; Lammek, B.; Kasprzykowski, F.; Gazis, D.; Schwartz, I. L. Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7. J. Med. Chem. 1983, 26, 555-559.
10. Bodansky, M.; Bath, R. J. Hindered amines in peptide synthesis. Synthesis of 7-glycine-oxytocin. J. Chem. Soc. Chem. Commun. 1968, 766-767.
11. Bespalova, Z. D.; Martynov, V. F.; Titov, M. I. New oxytocin analogues-7-Glycine-oxytocin and 7-D-leucine-oxytocin. Zh. Obs. Khim. 1968, 38, 1684-1687.
12. Walter, R.; Yamanaka, T.; Sakakibara, S. A neurohypophyseal hormone analogue with selective oxytocin-like activities and resistance to enzymatic inactivation: an approach to the design of peptide drugs. PNAS 1974, 71, 1901-1905.
13. Lowbridge, J.; Manning, M.; Haldar, J.; Sawyer, W. H. Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine] oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity. J. Med. Chem. 1977, 20, 120-123.
14. Rosamond, J. D.; Ferger, M. F. Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7. J. Med. Chem. 1976, 19, 873-876.
15. Moore, S.; Felix, A. M.; Meienhofer, J.; Smith, C. W.; Walter, R. Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7. J. Med. Chem. 1977, 20, 495-500.
16. Belec, L.; Slaninova, J.; Lubell, W. D. A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys6-Pro7 amide cis-isomer population. J. Med. Chem. 2000, 43, 1448-1455.
17. Shenderovich, M. D.; Koever, K. E.; Wilke, S.; Collins, N.; Hruby, V. J. Solution conformations of potent bicyclic antagonists of oxytocin by nuclear magnetic resonance spectroscopy and molecular dynamics simulations. J. Am. Chem. Soc. 1997, 119, 5833-5846.
18. Urry, D. W.; Ohnishi, M.; Walter, R. Secondary structure of the cyclic moiety of the peptide hormone oxytocin and its deamino analogue. PNAS 1970, 66, 111-116.
19. Oldziej, S.; Ciarkowski, J.; Liwo, A.; Shenderovich, M. D.; Grzonka, Z. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors. J. Recept. Signal Transduction Res. 1995, 15, 703-713.
20. Wood, S. P.; Tickle, I. J.; Treharne, A. M.; Pitts, J. E.; Mascarenhas, Y.; et al. Crystal structure analysis of deaminooxytocin: conformational flexibility and receptor binding. Science 1986, 232, 633-636.
21. Halab, L.; Lubell, W. D. Use of steric interactions to control peptide turn geometry. Synthesis of type VI beta-turn mimics with 5-tert-butylproline. J. Org. Chem. 1999, 64, 3312-3321.
22. Halab, L.; Lubell, W. D. Steric effects of 5-tert-butylproline in dipeptide mimics of type VI β-turns. Proceedings of the 25th European Peptide Symposium, Budapest, Hungary, 1999; pp 356-357.
23. Wöhr, T.; Wahl, F.; Nefzi, A.; Rohwedder, B.; Sato, T.; et al. Pseudo-prolines as a solubilizing, structure-disrupting protection technique in peptide synthesis. J. Am. Chem. Soc. 1996, 118, 9218-9227.
24. Dumy, P.; Keller, M.; Ryan, D. E.; Rohwedder, B.; Wöhr, T.; et al. Pseudo-prolines as a molecular hinge: Reversible induction of cis amide bonds into peptide backbones. J. Am. Chem. Soc. 1997, 119, 918-925.
25. Keller, M.; Sager, C.; Dumy, P.; Schutkowski, M.; Fischer, G. S.; et al. Enhancing the proline effect. Pseudo-prolines for tailoring cis/trans isomerization. J. Am. Chem. Soc. 1998, 120, 2714-2720.
26. Wittelsberger, A.; Keller, M.; Scarpellino, L.; Patiny, L.; Acha-Orbea, H.; et al. Pseudoprolines: Targeting a cis conformation in a mimetic of the gp120 V3 loop of HIV-1. Angew. Chem., Int. Ed. 2000, 39, 1111-1115.
27. Haack, T.; Mutter, M. Serine derived oxazolidines as secondary structure disrupting, solubilizing building blocks in peptide synthesis. Tetrahedron Lett. 1992, 33, 1589-1592.
28. Nefzi, A.; Schenk, K.; Mutter, M. Pseudo-proline: Temporary insertion of a cis-amide bond into a peptide backbone. Protein Pept. Lett. 1994, 1, 66-69.
29. Kaduk, C.; Wenschuh, H.; Beyermann, M.; Forner, K.; Carpino, L. A.; et al. Synthesis of Fmoc-amino acid fluorides via DAST, an alternative fluorinating agent. Lett. Pept. Sci. 1995, 2, 285-288.
30. Balacco, G. SwaN-MR: From infancy to maturity. Mol. Biol. Today 2000, 1, 23-28.
31. Holton, P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 1948, 3, 328-334.
32. Rose, J. P.; Wu, C. K.; Hsiao, C. D.; Breslow, E.; Wang, B. C. Crystal structure of the neurophysin-oxytocin complex. Nat. Struct. Biol. 1996, 3, 163.
33. Cheng, Y. C.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099-3108.
34. Tong, Y.; Olczak, J.; Zabrocki, J.; Gershengorn, M. C.; Marshall, G. R.; et al. Constrained peptidomimetics for TRH: cis-peptide bond analogues. Tetrahedron 2000, 56, 9791-9800.
35. Bax, A.; Davis, D. G. Practical aspects of two-dimensional transverse NOE spectroscopy. J. Magn. Res. 1985, 63, 207-213.
36. Bax, A.; Davis, D. G. Assignment of complex proton NMR spectra via two-dimensional homonuclear Hartmann-Hahn spectroscopy. J. Am. Chem. Soc. 1985, 107, 2820-2821.
37. Derome, A.; Williamson, M. Rapid-pulsing artifacts in double-quantum-filtered COSY. J. Magn. Res. 1990, 88, 177-185.
38. Hwang, T.-L.; Shaka, A. J. Water suppression that works. Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J. Magn. Reson. Ser. A 1995, 112, 275-279.
39. Balacco, G. SwaN-MR: A complete and expansible NMR software for the Macintosh. J. Chem. Inf. Comput. Sci. 1994, 34, 1235-1241.
40. Lewis, N. J.; Inloes, R. L.; Hes, J.; Matthews, R. H.; Milo, G. Synthetic sulfur-containing amino acids. Inhibition of transport systems in S37 ascites tumor cells. J. Med. Chem. 1978, 21, 1070-1073.
41. Fields, G.; Noble, R. Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990, 35, 161-214.
42. Sieber, P. A new acid-labile anchor group for the solid-phase synthesis of C-terminal peptide amides by the Fmoc method. Tetrahedron Lett. 1987, 28, 2107-2110.
43. Munsick, R. A. Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology 1960, 66, 451-457.
44. Dekanski, J. The quantitative assay of vasopressin. Br. J. Pharmacol. 1952, 7, 657-571.
45. Slaninova, J. Fundamental biological evaluation. Handbook of Neurohypophyseal Hormone Analogues; CRC Press: Boca Raton, FL, 1987; pp 83-107.
46. Fahrenholz, F.; Boer, R.; Crause, P.; Fritzsch, G.; Grzonka, Z. Interactions of vasopressin agonists and antagonists with membrane receptors. Eur. J. Pharmacol. 1984, 100, 47-58.
47. Fahrenholz, F.; Hackenberg, M.; Muller, M. Identification of a myometrial oxytocin-receptor protein. Eur. J. Biochem. 1988, 174, 81-85.
48. Soloff, M. S.; Swartz, T. L. Characterization of a proposed oxytocin receptor in the uterus of the rat and sow. J. Biol. Chem. 1974, 249, 1376-1381.
49. Elands, J.; Barberis, C.; Jard, S.; Tribollet, E.; Dreifuss, J. J.; et al. 125I-labeled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: A selective oxytocin receptor ligand. Eur. J. Pharmacol. 1988, 147, 197-207.
50. Chan, W. Y.; O'Connell, M.; Pomeroy, S. R. Effects of the estrous cycle on the sensitivity of rat uterus to oxytocin and desaminooxytocin. Endocrinology 1963, 72, 279-282.
51. Wenger, R. M.; France, J.; Bovermann, G.; Walliser, L.; Widmer, A.; Widmer, H. The 3D structure of a cyclosporin analogue in water is nearly identical to the cyclophilin-bound cyclosporin conformation. FEBS Lett. 1994, 340, 255-259.